Arbutus Biopharma Corporation Common Stock (ABUS)

FairStock Score: 34/100 — RISKY

Key Financials

Strengths

• High return on equity of 94.7% demonstrating efficient capital deployment
• Conservative balance sheet with debt-to-equity of just 0.02, providing financial flexibility
• Altman Z-Score of 8.6 confirms minimal bankruptcy risk and strong solvency

Concerns

• Trades significantly above Graham Number ($3) with negative 58% margin of safety—limited downside protection
• Currently unprofitable—sustained losses could lead to dilutive capital raises or balance sheet deterioration
• Revenue declining at 33.2% year-over-year signals potential demand weakness or market share loss
• Weak Piotroski F-Score of 3/9 suggests deteriorating financial quality across multiple dimensions

AI Analysis

Arbutus Biopharma Corporation Common Stock is a micro-cap healthcare company valued at $847 million. Revenue stands at $191 million, though the company is currently unprofitable. From a quality standpoint, Arbutus shows weak Piotroski F-Score of 3/9 signaling deteriorating fundamentals and Altman Z-Score of 8.6 confirms fortress-level solvency. On valuation, the stock is deeply undervalued on a P/E basis at 5.2x, with trades above its Graham Number with a negative 58% margin. Growth dynamics show revenue growing at -33.2% and profit growth of 70.0%. Our composite FairStock Score of 34/100 reflects below-average fundamentals overall. This combination of reasonable valuation, solid returns, and conservative leverage makes it worth a closer look for value-oriented portfolios.

Bull Case

The market underappreciates Arbutus's consistent 95% ROE at just 5x earnings—a re-rating toward sector peers could unlock 30-50% upside. Operational leverage in the business model means incremental revenue growth could disproportionately boost bottom-line profitability.

Bear Case

Without a clear path to profitability, continued cash burn forces either dilutive equity raises or debt accumulation that destroys shareholder value. Regulatory changes, input cost inflation, or demand normalization represent underappreciated risks that could materially impact forward estimates.

Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer